Focal Adhesion Kinase (FAK)
Focal adhesion kinase (FAK), a non-receptor protein-tyrosine kinase found in virtually all mammalian cells (Mitra et al. 2005; Frame et al. 2011) and crucial to integrin-based signaling (Alanko and Ivaska 2016). FAK was originally identified in 1990 as an ~125 kDa (p125/pp125) phosphoprotein (Kanner et al. 1990). FAK was later shown to be a cytosolic protein mostly accumulated at focal adhesions at the cell-matrix interface, and it was designated pp125FAK (Schaller et al. 1992). An increase in tyrosine phosphorylation of pp125FAK was detected during cell adhesion to fibronectin (Hanks et al. 1992). Furthermore, cells treated with a specific protein-tyrosine kinase inhibitor herbimycin A led to a decrease in focal adhesion and stress fiber formation (Burridge et al. 1992). These earlier observations thus illustrate that tyrosine phosphorylation of FAK plays a role in cytoskeletal...
This work was supported by grants from the National Institutes of Health, NICHD, R01 HD056034 to C.Y. C., and U54 HD029990 Project 5 to C.Y.C.
- Beardsley A, Robertson DM, O’Donnell L. A complex containing alpha6beta1-integrin and phosphorylated focal adhesion kinase between Sertoli cells and elongated spermatids during spermatid release from the seminiferous epithelium. J Endocrinol. 2006;190:759–70.PubMedPubMedCentralCrossRefGoogle Scholar
- Brown MC, Perrotta JA, Turner CE. Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding. J Cell Biol. 1996;135:1109–23.PubMedPubMedCentralCrossRefGoogle Scholar
- Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30:1527–33.PubMedPubMedCentralCrossRefGoogle Scholar
- Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. 2016.Google Scholar
- Kratimenos P, Koutroulis I, Marconi D, Syriopoulou V, Delivoria-Papadopoulos M, Chrousos GP, et al. Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase–Src–Paxillin system. Expert Opin Ther Targets. 2014;18:1395–406.PubMedPubMedCentralGoogle Scholar
- Mui KL, Bae YH, Gao L, Liu SL, Xu T, Radice GL, et al. N-Cadherin Induction by ECM Stiffness and FAK Overrides the Spreading Requirement for Proliferation of Vascular Smooth Muscle Cells. Cell Rep. 2015.Google Scholar
- Taylor JM, Hildebrand JD, Mack CP, Cox ME, Parsons JT. Characterization of graf, the GTPase-activating protein for rho associated with focal adhesion kinase. Phosphorylation and possible regulation by mitogen-activated protein kinase. J Biol Chem. 1998;273:8063–70.PubMedPubMedCentralCrossRefGoogle Scholar
- Xiao X, Mruk DD, Wong CK, Cheng CY. Germ cell transport across the seminiferous epithelium during spermatogenesis. Physiology (Bethesda). 2014;29:286–98.Google Scholar
- Xu LH, Yang X, Bradham CA, Brenner DA, Baldwin Jr AS, Craven RJ, et al. The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem. 2000;275:30597–604.PubMedPubMedCentralCrossRefGoogle Scholar